Novo Nordisk A/S ADR (NVO) Stock Price, Quote & News

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 45 44 44 88 88

Website: www.novonordisk.com

Address:

Novo Alle 1, Bagsvaerd, Denmark

ospreyeye Jul. 21 at 3:27 AM

$NVO >> Daily Chart >> Pulled back to test 300 SMA @ 49.38 support after closing above If support holds this is the load/reload zone Closing below would signal more consolidation snd possible pullback to the middle Bollinger Band at 48.92 As long as the middle bb is holding the up trend should continue If the 300 SMA holds the 400 SMA @ 54.51 = target 🎯 $SPY $IBB $LABU $LABD

0 · Reply

ContrarianLife Jul. 21 at 12:37 AM

$NVO Not one post during entire trading period today on a $220B cap business? 😂wtf is going on.

0 · Reply

Hooooooold Jul. 20 at 9:31 PM

$NVO uhhh up 30% past months, So much losing. but please do short + cover. Good luck with the earning uprades.

0 · Reply

sundimeng Jul. 20 at 9:04 PM

$NVO is it even alive?

0 · Reply

Swimmingincash Jul. 20 at 7:26 PM

$NVO time to load more Puts on this circus act. Can’t hold $50, Wall Street doesn’t give a shit about its EU or India approvals. It is, what it is. If you fight “what should be” in the market, you lose. Every time.

0 · Reply

ETAlpha Jul. 20 at 6:59 PM

Battle for $50! $NVO tests a key support zone as bulls fight to stabilize the next move. Novo Nordisk ($NVO) slips -1.01% to $49.81 as pharma rotation creates short-term pressure. The $50 psychological level remains the key battle line. Volume action shows buyers defending demand zones. Price action tells the story before headlines follow. Watch confirmation above support for the next trend signal. More market insights on my profile.

0 · Reply

MarketMaestro1 Jul. 20 at 6:58 PM

The market often needs multiple quarters of earnings, execution, and guidance before sentiment catches up. Long consolidations are not always bearish. Historically, strong companies that build a solid base can experience powerful breakouts once the narrative changes. Names with similar setups worth watching: $BABA $ZETA $NVO $BIDU $SE The biggest opportunities often appear when the fundamentals improve before the market fully recognizes the change. Patience + conviction matter.

0 · Reply

Maverickyo1 Jul. 20 at 6:51 PM

$NVO that 50 call wall is still causing pain

0 · Reply

EquityVoyager_1 Jul. 20 at 6:32 PM

Long Consolidation = Potential Breakout Setup Extended periods of sideways trading often create stronger moves once momentum returns. Stocks currently showing similar technical structures: $BABA Building a long-term base $ZETA Tight consolidation with breakout potential $NVO Watching for renewed momentum $BIDU Holding a key setup zone $SE Similar accumulation pattern Patience matters. When long consolidations finally break, the next move can be powerful. If you would like to learn more about marketing strategies, please visit my personal webpage.

0 · Reply

Kocatka Jul. 20 at 4:29 PM

$LXRX PDUFA or Buyout w $NVO ? Silence is Deafening!

0 · Reply

Novo Nordisk price target raised to DKK 330 from DKK 290 at Citi

2026-07-20T14:42:10.785Z - 13 hours ago

Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry

Sat, 18 Jul 2026 16:00:15 -0400 - 2 days ago

One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends

Sat, 18 Jul 2026 15:45:00 -0400 - 2 days ago

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

2026-07-17T18:30:00.000Z - 3 days ago

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win

Fri, 17 Jul 2026 12:20:54 -0400 - 3 days ago

Novo Nordisk to launch lower-cost Ozempic copy in South Africa

Fri, 17 Jul 2026 04:39:21 -0400 - 3 days ago

India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease

2026-07-16T12:00:29.000Z - 4 days ago

The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?

2026-07-16T05:22:00.000Z - 4 days ago

Novo Nordisk Wins European Commission Nod For Wegovy Pill In Adult Obesity /Overweight

2026-07-15T22:09:21.000Z - 5 days ago

Novo Nordisk AS (NVO) Shares Surge 3.0% -- What GF Score of 76 Tells Investors

2026-07-15T18:55:35.000Z - 5 days ago

Novo Nordisk (NVO) Secures EU Approval for Wegovy Oral and Injectable Treatments

2026-07-15T17:30:04.000Z - 5 days ago

NVO: Novo Nordisk Secures EU Approval for Wegovy Pill in Obesity Treatment

Wed, 15 Jul 2026 12:40:54 -0400 - 5 days ago

Novo Nordisk wins EU approval for Wegovy weight-loss pill

2026-07-15T16:00:13.000Z - 5 days ago

Novo Nordisk announces European Commission approval of Wegovy pill

Wed, 15 Jul 2026 11:06:17 -0400 - 5 days ago

India's Sun Pharma wins South Africa approval to launch generic Ozempic

2026-07-15T14:59:26.000Z - 5 days ago

Novo Nordisk's (NVO) Wegovy Pill Dominates U.S. Market for Oral Weight Loss Drugs

2026-07-15T14:54:09.000Z - 5 days ago

Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions

2026-07-15T09:30:50.000Z - 5 days ago

Foundayo vs. Wegovy: Eli Lilly Trails Novo Nordisk in Weight Loss Drug Market

Tue, 14 Jul 2026 20:00:00 -0400 - 6 days ago

It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.

2026-07-12T15:26:48.000Z - 8 days ago

New Data on Hemophilia Treatment from Novo Nordisk (NVO)

2026-07-12T15:16:49.000Z - 8 days ago

Weight-loss implant could one day replace Ozempic injections

2026-07-12T14:10:13.000Z - 8 days ago

Novo Nordisk announces new data from phase 3 FRONTIER4 study of denecimig

2026-07-12T09:59:46.000Z - 8 days ago

Novo Nordisk’s Hemophilia Drug Delivers Strong Results, but Analysts See 10% Downside for NVO Stock

Sat, 11 Jul 2026 09:15:00 -0400 - 9 days ago

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026

Sat, 11 Jul 2026 08:00:01 -0400 - 9 days ago

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

2026-07-09T09:30:15.000Z - 11 days ago

India gets world's first once-a-week insulin: All about Novo Nordisk's Awiqli

Thu, 09 Jul 2026 02:23:43 -0400 - 11 days ago

Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises

2026-07-08T10:51:18.000Z - 12 days ago

NVO: Novo Nordisk Updates Semaglutide Label in Singapore

2026-07-08T09:20:10.000Z - 12 days ago

Novo Nordisk announces updated semaglutide label in Singapore

2026-07-07T21:30:00.000Z - 13 days ago

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Tue, 07 Jul 2026 16:00:00 -0400 - 13 days ago

3 Reasons to Buy Novo Nordisk Stock

2026-07-07T15:30:02.000Z - 13 days ago

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone

2026-07-07T13:56:59.000Z - 13 days ago

Vivani Medical (VANI) Partners with Novo Nordisk for Semaglutide Implant Study

2026-07-07T13:16:48.000Z - 13 days ago

Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139

2026-07-07T11:46:09.000Z - 13 days ago

Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139

VANI

2026-07-06T14:25:14.000Z - 14 days ago

Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBC

2026-07-06T12:15:15.000Z - 14 days ago

Wegovy weight-loss pill goes on sale at UK high street and online pharmacies

2026-07-02T15:02:02.000Z - 18 days ago

Novo Nordisk (NVO) Seeks Supplier Discounts to Boost Competitiveness

2026-07-01T17:55:31.000Z - 19 days ago

Medicare Expands Access to GLP-1 Drugs, Boosting Eli Lilly (LLY) and Novo Nordisk (NVO)

2026-07-01T13:58:03.000Z - 19 days ago

Eli Lilly (LLY) and Novo Nordisk (NVO) to Benefit from New Medicare GLP-1 Program

2026-07-01T10:49:07.000Z - 19 days ago

Novo Nordisk Stock (NVO) Rises as Medicare Starts Covering Obesity Drugs

LLY

2026-06-30T13:53:27.000Z - 20 days ago

Medicare Expands Coverage for GLP-1 Weight Loss Drugs Boosting Novo Nordisk (NVO)

Tue, 30 Jun 2026 05:00:01 -0400 - 20 days ago

Medicare will start covering obesity drugs for the first time. Here's what patients should know

2026-06-28T12:38:00.000Z - 22 days ago

Novo Nordisk: A Buy After The 340B Reset, With The Pill As Optionality

Sun, 28 Jun 2026 08:00:01 -0400 - 22 days ago

Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet

Fri, 26 Jun 2026 16:47:53 -0400 - 24 days ago

Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Fri, 26 Jun 2026 12:39:36 -0400 - 24 days ago

Swiss pharma at risk of US trade investigation, industry body says

Fri, 26 Jun 2026 10:45:46 -0400 - 24 days ago

GLP-1s linked to smell and taste impairment in diabetes patients

Fri, 26 Jun 2026 10:08:22 -0400 - 24 days ago

Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage

Thu, 25 Jun 2026 11:18:00 -0400 - 25 days ago

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees.

Jun 25, 2026, 5:07 AM EDT - 25 days ago

Novo's top US exec wants more insurance coverage for weight-loss drugs

NVO

Jun 22, 2026, 6:42 AM EDT - 4 weeks ago

South Africa court bars iDexis from selling compounded Ozempic in Novo Nordisk case

NVO

Jun 22, 2026, 5:30 AM EDT - 4 weeks ago

Doctors say that GLP-1 medications can prevent lifelong obesity and Type 2 diabetes in children—but there are some worries

LLY NVO

2026-06-19T11:15:41.000Z - 4 weeks ago

Novo Nordisk upgraded to Buy from Hold at Nordea

NVO

2026-06-17T16:00:43.000Z - 4 weeks ago

Novo Nordisk price target raised to DKK 325 from DKK 300 at Berenberg

NVO

Jun 17, 2026, 11:45 AM EDT - 4 weeks ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN LLY NVO TWST

Jun 16, 2026, 1:47 PM EDT - 4 weeks ago

Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion

NVO

Jun 16, 2026, 2:00 AM EDT - 4 weeks ago

Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO

NVO

Jun 13, 2026, 2:00 PM EDT - 5 weeks ago

The Next Phase Of The Obesity Drug Race

GPCR LLY NVO

Jun 13, 2026, 8:00 AM EDT - 5 weeks ago

Drugmakers race to find a place in the next wave of obesity drugs

AMGN NVO AZN LLY

Jun 11, 2026, 11:45 AM EDT - 5 weeks ago

Novo Nordisk hit by cyber incident, probes data breach

NVO

2026-06-11T15:42:34.000Z - 5 weeks ago

Novo Nordisk announces security incident on ‘limited number’ of systems

NVO

Jun 11, 2026, 11:42 AM EDT - 5 weeks ago

Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.

NVO

Jun 11, 2026, 11:30 AM EDT - 5 weeks ago

Novo Nordisk A/S: IT Security incident at Novo Nordisk

NVO

2026-06-11T15:12:47.000Z - 5 weeks ago

Novo Nordisk reports Wegovy pill approved in UK

NVO

Jun 11, 2026, 11:03 AM EDT - 5 weeks ago

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

NVO

Jun 11, 2026, 11:01 AM EDT - 5 weeks ago

UK health regulator approves Novo Nordisk's weight-loss pill

NVO

Jun 11, 2026, 7:14 AM EDT - 5 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Jun 11, 2026, 6:03 AM EDT - 5 weeks ago

Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

LLY NVO

Jun 10, 2026, 6:16 AM EDT - 5 weeks ago

Novo Nordisk faces off in court with South African weight-loss drug compounder

NVO

Jun 9, 2026, 2:42 PM EDT - 5 weeks ago

Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before

NVO

Jun 9, 2026, 2:40 PM EDT - 5 weeks ago

Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy

NVO

Jun 9, 2026, 1:30 PM EDT - 5 weeks ago

Novo Nordisk CEO: We are a cardiometabolic powerhouse

NVO

Jun 9, 2026, 9:20 AM EDT - 5 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO PFE

Jun 8, 2026, 5:05 PM EDT - 6 weeks ago

Use of GLP-1 drugs early in pregnancy should not cause alarm

LLY NVO

Jun 8, 2026, 10:30 AM EDT - 6 weeks ago

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

LLY NVO

Jun 8, 2026, 2:42 AM EDT - 6 weeks ago

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

NVO

Jun 7, 2026, 7:35 PM EDT - 6 weeks ago

The Wegovy pill is still dominating the GLP-1 pill market

NVO

Jun 7, 2026, 7:30 PM EDT - 6 weeks ago

Novo Nordisk Transcript: Investor update

Jun 7, 2026, 7:30 PM EDT - 6 weeks ago

Novo Nordisk Slides: Investor update

Jun 3, 2026, 6:05 AM EDT - 6 weeks ago

Focus: GLP-1 drugs may have a beneficial effect across many types of cancer

LLY NVO

Jun 3, 2026, 4:33 AM EDT - 6 weeks ago

Novo Nordisk launches Wegovy in UAE

NVO

Jun 3, 2026, 3:42 AM EDT - 6 weeks ago

Novo Nordisk rolls out Wegovy pill in the UAE — its first market outside the U.S.

NVO

Jun 3, 2026, 3:03 AM EDT - 6 weeks ago

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE

NVO

Jun 3, 2026, 2:00 AM EDT - 6 weeks ago

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

NVO

Jun 2, 2026, 5:43 PM EDT - 6 weeks ago

Exclusive: Cigna drops coverage of GLP-1 obesity drugs for its own employees

CI LLY NVO

May 26, 2026, 4:41 AM EDT - 7 weeks ago

Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke

NVO

May 22, 2026, 1:30 PM EDT - 2 months ago

Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)

NVO

May 22, 2026, 9:11 AM EDT - 2 months ago

Novo Nordisk uses AI to fast-track drug launches, expand India role

NVO

May 22, 2026, 9:09 AM EDT - 2 months ago

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

NVO

May 22, 2026, 8:30 AM EDT - 2 months ago

European Regulator Backs Novo Nordisk's Wegovy Weight-Loss Pill

NVO

May 22, 2026, 6:47 AM EDT - 2 months ago

European medicines regulator recommends approval for Novo's Wegovy pill

NVO

May 21, 2026, 6:02 AM EDT - 2 months ago

Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say

LLY NVO

May 18, 2026, 9:44 AM EDT - 2 months ago

US Supreme Court rebuffs pharma challenge to Biden-era drug price

AZN BMY NVO NVS

ospreyeye Jul. 21 at 3:27 AM

0 · Reply

ContrarianLife Jul. 21 at 12:37 AM

$NVO Not one post during entire trading period today on a $220B cap business? 😂wtf is going on.

0 · Reply

Hooooooold Jul. 20 at 9:31 PM

$NVO uhhh up 30% past months, So much losing. but please do short + cover. Good luck with the earning uprades.

0 · Reply

sundimeng Jul. 20 at 9:04 PM

$NVO is it even alive?

0 · Reply

Swimmingincash Jul. 20 at 7:26 PM

0 · Reply

ETAlpha Jul. 20 at 6:59 PM

0 · Reply

MarketMaestro1 Jul. 20 at 6:58 PM

0 · Reply

Maverickyo1 Jul. 20 at 6:51 PM

$NVO that 50 call wall is still causing pain

0 · Reply

EquityVoyager_1 Jul. 20 at 6:32 PM

0 · Reply

Kocatka Jul. 20 at 4:29 PM

$LXRX PDUFA or Buyout w $NVO ? Silence is Deafening!

0 · Reply

jam500 Jul. 20 at 3:21 PM

$NVO strong

0 · Reply

Hooooooold Jul. 20 at 3:10 PM

$NVO holding strong

0 · Reply

NVONOW Jul. 20 at 2:44 PM

$NVO 528 shares @ 53.69 average, let's go!

0 · Reply

NorthstarT1D Jul. 20 at 2:13 PM

$NVO brutal stop loss raid

0 · Reply

wombat26 Jul. 20 at 1:53 PM

$NVO so we're back to last earnings price

0 · Reply

michele1208 Jul. 20 at 1:44 PM

$NVO 50$ need to hold!!

0 · Reply

Makingmillions192 Jul. 20 at 12:59 PM

$LEXX Human Study #7 is officially completed 🤝 Now that the active patient dosing window is completely wrapped up, the transition to data compilation and unblinding is officially underway. Here is the expected countdown schedule for the late-summer data drops: Late August 2026: Human Study #7 (GLP-1-H26-7) data drops. This remains the headline event comparing DehydraTECH tablets and capsules head-to-head against commercial Wegovy. Late August / Early September 2026: Animal Study #2 (GLP-1-A26-2) data drops. This massive 18-arm study evaluates how DehydraTECH pairs with tomorrow's multi-agonist blockbusters—Eli Lilly's retatrutide and Novo Nordisk's amycretin. Early September 2026: Animal Study #1 (GLP-1-A26-1) data drops. This 11-arm study will show performance results for alternative, non-SNAC formulation carriers and map out drug absorption directly into brain tissue. Everything is compressed into roughly a 3-to-4 week window 🚀 Let’s make a deal 💰 📈 $LLY $NVO $RANI

2 · Reply

snidely Jul. 20 at 12:55 PM

$NVO just go to $60 already

0 · Reply

TheVoic Jul. 20 at 11:03 AM

$NVO gap filled ✅

1 · Reply

AJavier Jul. 20 at 9:18 AM

$NVO vamos!

0 · Reply

Alon_R Jul. 20 at 8:52 AM

$XERS $NVO Ozempic - XP-8121 (Analogy)-> Huge established chronic market ✔️ Old generic treatment paradigm ✔️ Differentiated injectable formulation✔️ Less frequent dosing(once-weekly)✔️ Improved patient experience✔️ Premium branded product✔️ Levothyroxine is enormous in terms of treatment volume, generating more than 100M prescriptions annually in the United States alone. While I do not know how the finding that 72% of patients in the clinical trial showed a strong preference to use once-weekly injectable XP-8121 rather than the regular oral option will translate into revenue once XP-8121 is commercialized, analyst Leland Gershell from Oppenheimer said that even just 5% market penetration in the U.S. alone could be equivalent to ~ $1.3B in annual revenue. And what if the potential is (just) 15% in the U.S.? We are already talking about theoretically ~$3.9B annually. And what about other developed healthcare markets? Theoretically, that could translate to $7-8B in annual revenue.

0 · Reply

Mandalo Jul. 20 at 5:39 AM

$RANI is setting up for a massive breakout as giants like Eli Lilly, Novo Nordisk, and Viking Therapeutics dominate the injection space. By transforming painful biologics and obesity treatments into simple oral capsules, Rani’s robotic pill platform is the ultimate disruptor. The Ultimate Biotech Play: The Injection Killer: Big Pharma ($LLY, $NVO,$VKTX) relies heavily on needles. Rani offers a painless oral alternative WITHOUT PROBLEMS. Massive TAM: Direct threat—or perfect buyout target—for companies leading the GLP-1 and chronic disease markets. Clinical Catalyst: Upcoming data could trigger a massive short squeeze. Smart money is accumulating before the big players try to license this tech. Don't miss the launch. 🚀 #RANI #Biotech #Bullish

5 · Reply

Market Cap	224.68B
Revenue (ttm)	46.79B
Net Income (ttm)	15.51B
EPS (ttm)	N/A
PE Ratio	12.77
Forward PE	15.22
Profit Margin	33.14%
Debt to Equity Ratio	0.72

Volume	7,298,900
Avg Vol	12,201,103
Day's Range	N/A - N/A
Shares Out	4.47B
Stochastic %K	38%
Beta	0.77
Analysts	Hold
Price Target	$47.28